Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news


Novartis inks $50m local deal

Posted 20 November 2020

Homegrown biotech Mesoblast has entered into an exclusive worldwide license and collaboration agreement with Novartis potentially worth up to US$1.255 billion (AU$1.7 billion) for the development, manufacture and commercialisation of its mesenchymal stem cell product remestemcel-L.

Shares in the Aussie biotech soared when the Australian sharemarket opened today (Friday), up 16 per cent from $3.26 to $3.79 on announcement Novartis will pay US$50 million upfront, including US$25 million in equity as part of the agreement terms.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Top of the Hill
Picking the path out of Covid
Now is not the time for leaders to play it safe
Special Report
Aust Covid Vaccine Tracker
UPDATE: Gilead hits back at WHO over remdesivir
Approvals Action
Trio of new drugs on ARTG
Roche, Seqirus, Clinuvel enlarge local portfolios